Myriad Genetics, Inc.

Myriad Mypath, LLC

Laboratory Corporation of America Holdings

Myriad International Gmbh

Alexander Gutin

Kirsten Timms

Julia Reid

Jerry Lanchbury

Victor Abkevich

Steven Stone

Susanne Wagner

Darl Flake

Benjamin Roa

Michael Bryan Warf

Marsel Scheer

Ralf Kronenwett

Eric Sasso

Paul Scott Eastman

Andrey Zharkikh

David Chernoff

Ching Chang Hwang

Esther Elishaev

Alfred Guirguis

Julie A DeLoia

Steve Stone

Bryan Warf

Jutta Reid

This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.

Methods and materials for assessing homologous recombination deficiency

Provided herein are methods for assessing response to inflammatory disease therapy. The methods include performing immunoassays to generate scores based on quantitative data for expression of biomarkers relating to inflammatory biomarkers to assess disease activity in inflammatory diseases, e.g., rheumatoid arthritis. Also provided are methods of adjusting disease activity scores to account for variables that can influence such scores.

Adjusted multi-biomarker disease activity score for inflammatory disease assessment

Panels of biomarkers, methods and systems are disclosed for determining gene expression, and diagnosing and treating melanoma.

Genes and gene signatures for diagnosis and treatment of melanoma

Provided herein are methods for predicting chemotherapy benefit. The invention predicts chemotherapy benefit based on the expression analysis of biomarkers, e.g., RNA biomarker transcription analysis, taken from a tumor sample. The biomarker expression data can be combined with clinical variables, e.g., tumor size and nodal status, to generate a profile that predicts the benefit of including chemotherapy as a treatment decision.

Method of using biomarkers and clinical variables for predicting chemotherapy benefit

Genes and gene signatures for diagnosis and treatement of melanoma

Methods and systems for detecting allelic imbalance using nucleic acid sequencing are provided.

Methods and materials for assessing allelic imbalance

Biomarkers and methods using the biomarkers for classifying cancer in a patient (e.g., predicting the risk of cancer-specific death or cancer recurrence) are provided.

Gene signatures for cancer prognosis

This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.

Method of treating cancer

Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.

Method for treating cancer

Growing community of inventors

Salt Lake City, UT, United States of America

Alexander Gutin